ClinicalTrials.gg
Not yet recruitingNCT07896577Updated Oct 27, 2026

Prophylactic PPI Use After EUS-GE Procedure

An interventional study of Esomeprazole and Placebo in Malignant Gastric Outlet Obstruction, sponsored by Changhai Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Changhai Hospital · Not applicable, Interventional, and Treatment

Updated Oct 27, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
273
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to compare the 6-month cumulative incidence of mucosal erosion or ulcer involving the anastomosis and LAMS flange in patients with and without 6-month prophylactic PPI treatment following EUS-GE, and to assess whether routine PPI use provides clear mucosal-protective effects

02

Conditions studied

  • Malignant Gastric Outlet Obstruction

Keywords

  • EUS-GE
03

In context

Gastric Outlet Obstruction

38 studies on the registry are indexed under Gastric Outlet Obstruction; 14 are open to participants now.

This study's planned enrollment of 273 is above the median of 69 across 28 interventional studies indexed under Gastric Outlet Obstruction.

Browse Gastric Outlet Obstruction studies →

Lead sponsor

Changhai Hospital is the lead sponsor of 355 studies on the registry; 137 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥18 years, male or female, with no gender restriction.
  • Planned for EUS-GE for malignant gastric outlet obstruction (GOO).
  • Technically successful EUS-GE: correct stent position is intra-operatively confirmed comprehensively via fluoroscopy-aided contrast injection through the stent and dye solution flowing into the stomach through the stent; no severe adverse events requiring urgent surgical or interventional management occur during the procedure.
  • Planned LAMS indwelling for at least 6 months, and willingness to undergo scheduled gastroscopy evaluations at 3-month and 6-month post-procedure.
  • Able to take oral study medications per protocol after significant relief of obstructive symptoms.
  • The subject or legal representative is fully informed and provides written

Exclusion criteria

Exclusion Criteria:

  • Definite indication for long-term proton-pump inhibitor (PPI) therapy that cannot be discontinued or de-escalated, including active peptic ulcer disease, recent upper gastrointestinal bleeding, Los Angeles grade C/D reflux esophagitis, Zollinger-Ellison syndrome, antithrombotic or NSAID therapy judged by the investigator to require continuous gastric mucosal protection, etc.
  • Active gastric or duodenal ulcer, overt gastrointestinal bleeding within 7 days prior to enrollment, or unexplained persistent decline.
  • Ongoing treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or high-dose ; or inability to adjust anticoagulant and antiplatelet agents per study protocol.
  • > 1.5, count \< 50 × 10⁹/L, or other uncorrected severe coagulopathy.
  • Severe cardiac, pulmonary, hepatic or renal insufficiency; pregnancy or lactation.
  • to esomeprazole, other benzimidazole-class agents, or .
  • Concurrent participation in other interventional clinical trials that may affect the primary endpoint.
  • Poor compliance judged by the investigator; inability to complete electronic medication records or scheduled gastroscopic follow-up.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
273 participants (estimated)

Study arms

  • Active comparator
    PPI

    use PPI after the procedure for 6 months to prevent potential ulceration

    Drug: Esomeprazole

  • Placebo comparator
    non-PPI

    Placebo use after the procedure for 6 months

    Drug: Placebo

Interventions

  • Intravenous esomeprazole 40 mg (in 100 mL normal saline) on the day of procedure; after first oral intake, oral esomeprazole 20 mg twice daily, 30 min before meals, for 6 months.

  • DrugPlacebo

    Intravenous infusion of 100 mL normal saline on the day of procedure; after first oral intake, matching placebo (identical appearance, odor, weight, packaging) twice daily for 6 months.

06

What researchers measure

Primary outcomes

  1. mucosal injury

    anastomotic, gastric-side or jejunal-side erosion, ulcer, or associated bleeding

    Time frame: 6 months

Secondary outcomes

  1. Mechanical LAMS-related events

    tissue hyperplasia, stent ingrowth, flange embedding, ≥25% reduction in LAMS luminal diameter, food impaction, stent deformation or migration

    Time frame: 6 months

  2. reintervention

    Any EUS-GE-related reintervention and time to first EUS-GE-related reintervention

    Time frame: 6 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07896577
Lead sponsor
Changhai Hospital
Responsible party
Zhaoshen Li (Director, Department of Gastroenterology, Changhai Hospital, Naval Medical University, Changhai Hospital) — Principal investigator
First posted
Oct 27, 2026
Start date
Dec 2026 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Oct 27, 2026

Study contacts

JiaYi Ma, medical doctor
Contact
504043536@qq.com
+86-13621819595

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esomeprazole

Start the discussion